SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

AGM Statement

9 Sep 2014 07:00

RNS Number : 1350R
Oxford Instruments PLC
09 September 2014
 



Oxford Instruments plc

Chairman's AGM Statement 2014

 

 

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, is holding its annual general meeting today in which the Chairman, Nigel Keen will make the following statement:

 

"In June of this year we reached the end of the period covered by our 14 Cubed plan. The Group achieved the targeted 14% return on sales and compound annual revenue growth of 11% over the three years.

 

Also in June we gave more detail on our strategic direction focusing on the 'convergence of the sciences' where scientific research and technological development is increasingly being carried out at the nano-scale where atoms and molecules interact, blurring the boundaries between the traditional sciences. This is particularly true for the emerging field of nano-bio where we are seeing crossover between the disciplines of physics and biology. This increases the addressable market for our products and allows us to leverage the Oxford Instruments brand and distribution network.

 

We first entered the nano-bio field with the acquisition of Asylum Research in December 2012 and strengthened our position with the acquisition of Andor Technology plc in January of this year. Each company has products which operate in both the materials science and bio science markets.

 

I would like to take this opportunity to again welcome our new colleagues from Andor. The integration process has gone very well thanks to the effort put in by employees from both companies and I am pleased to report that Andor is performing well with orders ahead of expectations.

 

The successful integration of Andor and recovery in the United States markets has offset continued currency pressure caused by the strength of Stirling.

 

Today Sir Michael Brady retires from the Board. Mike's technical and business skills have been a fantastic asset to the Group over many years and his wise counsel will be missed. I would like to take this opportunity to thank him for all his efforts. Also, I would like to welcome Sir Richard Friend who is the Cavendish Professor of Physics at Cambridge University, and who joined the Board on 1 September.

 

 

Current Trading

 

Orders for the year to date continue to be ahead of the same period last year on both a constant currency organic basis and as reported.

 

In addition to the growth generated by the Andor acquisition, we have seen order growth year-on-year in North America and Europe in both Nanotechnology Tools and Industrial Products. Asian markets have been more difficult with growth in Industrial Products and a decline in Nanotechnology Tools, particularly in Japan where we are detecting a shift in government spending favouring infrastructure over research and development in the current year.

 

 

Outlook

 

The good order intake in the first half of the year underpins our revenue projections for the remainder of the year. This means that we expect the second half weighting usual in the Group to be more pronounced than usual."

 

 

 

Enquiries:

 

Oxford Instruments plc

Jonathan Flint, Chief Executive

Kevin Boyd, Group Finance Director

 

 

Tel: 01865 393200

 

MHP Communications

Rachel Hirst / Rory King

 

Tel: 020 3128 8100

 

 

Notes to Editors 

 

About Oxford Instruments plc

 

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for over 50 years, and its strategy is to effect the successful commercialisation of these ideas by bringing them to market in a timely and customer-focused fashion.

 

The first technology business to be spun out from Oxford University, Oxford Instruments is now a global company with over 2300 staff worldwide and is listed on the FTSE250 index of the London Stock Exchange (OXIG). Its objective is to be the leading provider of new generation tools and systems for the research and industrial sectors with a focus on nanotechnology. Its key market sectors include nano-fabrication and nano-materials. The company's strategy is to expand the business into the life sciences arena, where nanotechnology and biotechnology intersect

 

This involves the combination of core technologies in areas such as low temperature, high magnetic field and ultra high vacuum environments; Nuclear Magnetic Resonance; x-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; advanced growth, deposition and etching.

 

Oxford Instruments aims to pursue responsible development and deeper understanding of our world through science and technology. Its products, expertise, and ideas address global issues such as energy, environment, security and health.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUWRRRSUAKRUR
Date   Source Headline
25th Jul 20257:00 amPRNDirector/PDMR Shareholding
25th Jul 20257:00 amPRNTransaction in Own Shares
24th Jul 20257:00 amPRNTransaction in Own Shares
23rd Jul 20257:00 amPRNTransaction in Own Shares
22nd Jul 20257:00 amPRNTransaction in Own Shares
21st Jul 20257:00 amPRNTransaction in Own Shares
18th Jul 20257:00 amPRNTransaction in Own Shares
17th Jul 20257:00 amPRNTransaction in Own Shares
16th Jul 20257:00 amPRNTransaction in Own Shares
15th Jul 20257:00 amPRNTransaction in Own Shares
14th Jul 20257:00 amPRNTransaction in Own Shares
11th Jul 20251:35 pmPRNDirector/PDMR Shareholding
11th Jul 20257:00 amPRNTransaction in Own Shares
10th Jul 20257:00 amPRNTransaction in Own Shares
9th Jul 20257:00 amPRNTransaction in Own Shares
8th Jul 20257:00 amPRNTransaction in Own Shares
7th Jul 202510:30 amPRNHolding(s) in Company
7th Jul 20257:00 amPRNTransaction in Own Shares
4th Jul 20257:00 amPRNTransaction in Own Shares
3rd Jul 20257:00 amPRNTransaction in Own Shares
2nd Jul 20254:07 pmPRNDirector/PDMR Shareholding - purchase of shares
2nd Jul 20257:00 amPRNTransaction in Own Shares
1st Jul 202512:28 pmPRNBlocklisting - Interim Review
1st Jul 202512:28 pmPRNTotal Voting Rights
1st Jul 20257:00 amPRNTransaction in Own Shares
30th Jun 20257:00 amPRNTransaction in Own Shares
27th Jun 20257:00 amPRNTransaction in Own Shares
26th Jun 20252:02 pmPRNBlock Listing Application
26th Jun 20257:00 amPRNTransaction in Own Shares
25th Jun 202512:14 pmPRNPublication of Annual Report 2025 and Notice of Annual General Meeting 2025
25th Jun 20257:00 amPRNCommencement of Share Buyback
24th Jun 20259:30 amPRNHolding(s) in Company
20th Jun 20257:00 amPRNDirector/PDMR Shareholding
18th Jun 20254:30 pmPRNHolding(s) in Company
13th Jun 20257:00 amRNSPreliminary Results
12th Jun 20252:43 pmRNSAnnouncement of Preliminary Results
11th Jun 20252:38 pmPRNDirector/PDMR Shareholding
10th Jun 20254:12 pmPRNHolding(s) in Company
10th Jun 20257:00 amRNSDelay to announcement of preliminary results
10th Jun 20257:00 amRNSSale of Oxford Instruments’ quantum business
2nd Jun 202512:33 pmPRNTotal Voting Rights
13th May 20253:45 pmPRNDirector/PDMR Shareholding
22nd Apr 20253:40 pmPRNHolding(s) in Company
17th Apr 20251:40 pmPRNHolding(s) in Company
16th Apr 20257:00 amRNSTrading Update
15th Apr 20251:30 pmPRNHolding(s) in Company
14th Apr 20253:33 pmPRNDirector/PDMR Shareholding
10th Apr 20257:00 amRNSHolding(s) in Company
1st Apr 20257:00 amRNSTotal Voting Rights
25th Mar 202512:35 pmPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.